Searched for
CIPLAS
Reliance Industries among 5 Nifty stocks showing bullish RSI upswingFive stocks in the Nifty50 pack featured in the RSI Trending Up scan on June 22 after showing improving momentum. The RSI moved above the 5...- Market trading guide: Cipla among 2 stock recommendations for TuesdayCipla and Knowledge Marine feature among analysts' top stock picks for Tuesday, backed by bullish technical breakouts, improving momentum i...
- Cipla shares jump 4% as Citi puts stock on 90-day catalyst watch. What's driving the optimism?Cipla's stock surged following Citi's 'Buy' rating and a 90-day Positive Catalyst Watch. The brokerage anticipates growth from potential US...
- Sell or Hold: Citi maintains buy on Cipla; Motilal Oswal recommends buy on RIL post AGMBrokerages remain bullish on Cipla and Reliance Industries, citing strong growth drivers and attractive valuations. Citi highlights regulat...
- These large- mid- and small-cap stocks can give more than 25% return in 1 year, according to analystsAs the bulls attempt another serious comeback, the market again faces a familiar question: Are valuations still too high, or have they reac...
- India among Asia-Pacific's most AI-ready healthcare markets as demand for coordinated care rises: BainIndia is emerging as one of the most AI-ready healthcare markets in the Asia-Pacific region, with a growing number of consumers using gener...
- Cipla appoints health chief Shivam Puri to lead One India businessCipla has appointed Shivam Puri as the new Chief Executive Officer for its One India Business. This significant leadership change will take...
- Global drugmakers rush to boost US presence as tariff threat loomsGlobal drug companies are boosting U.S. production and stockpiling medicines. This is a response to potential tariffs on branded drugs. Com...
- Parag Parikh Flexi Cap Fund : ITC, HDFC Bank and Cipla among stocks bought and sold in MayParag Parikh Flexi Cap Fund, India's largest active mutual fund, increased exposure to several banking and IT stocks in May, trimmed its ho...
- India raises price cap on cancer drugs to tackle shortageIndia's drug price regulator has increased the ceiling prices of cancer drugs cisplatin and carboplatin by 50% to tackle shortages caused b...
- Nifty in control of FIIs? The unlucky 13 bluechips facing the hardest institutional selloffForeign investors have significantly reduced holdings in many Nifty companies since September 2024. This has impacted top blue-chip stocks,...
- Parag Parikh Flexi Cap Fund raises stake in ITC, HDFC Bank and 14 other stocks in MayParag Parikh Flexi Cap Fund, India’s largest active flexi-cap scheme by AUM, raised exposure to ITC, HDFC Bank and 14 other stocks in May, ...
- Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplashIndian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...
- Indian cancer patients battle shortage of key drugs as platinum costs surgeCancer patients in India are struggling to find essential platinum-based drugs. A surge in global platinum prices and supply chain issues a...
- AI video startup TrueFan raises $10 million led by Baring PE, Z3PartnersGurugram's TrueFan AI secured $10 million, valuing it at $40 million, to fuel its AI-generated video platform. Serving over 100 enterprises...
- Dividend alert! Last date to buy RIL, HDFC AMC and 14 other stocks for dividend rewards. Do you own any?A total of 16 stocks, including Reliance Industries, HDFC AMC, Bank of Baroda and others, are set to turn ex-dividend on June 5, making tod...
- Zaynich's blockbuster potential lifts Wockhardt's long-term outlookWockhardt's novel antibiotic, Zaynich, has received USFDA approval after a 12-year effort, sparking hopes for a turnaround after years of n...
- Bonus issues, dividends and more: Reliance Industries, Trent among 20 stocks turning ex-date this weekReliance Industries, Trent, and 18 other stocks are set to turn ex-date this week for corporate actions including dividends and bonus issue...
- Cipla is aiming for 40-50 global product filings in three years, says MD Achin GuptaCipla is charting its next growth phase with a strong focus on innovation, complex generics, and biosimilars. The company plans significant...
- Innovation, biosimilars, complex generics to drive Cipla's growth: Achin Gupta, MD & Group CEOAs Cipla approaches its centenary, the company is redefining its strategy by prioritizing innovation to amplify revenues. With ambitions to...
Load More
